score,metric,date,value,year,sentence,number
0.7917067408561707,marketable securities,"may 31, 2021 and 2020",$43.1 billion,2021,"cash, cash equivalents and marketable securities were $46.6 billion and $43.1 billion as of may 31, 2021 and 2020, respectively",43100000000.0
0.5941126346588135,r&d value,2019,$6.0 billion,2019,"in fiscal 2021, 2020 and 2019, we invested $6.5 billion, $6.1 billion and $6.0 billion, respectively, in research and development to enhance our existing portfolio of offerings and products and to develop new technologies and services",6000000000.0
0.5634774565696716,cash on balance sheet,"fiscal 2021, 2020",$1.7 billion,2020,"total cash received as a result of stock option exercises was approximately $1.7 billion, $1.5 billion and $2.0 billion for fiscal 2021, 2020 and 2019, respectively",1700000000.0
0.5634774565696716,cash on balance sheet,2019,$2.0 billion,2019,"total cash received as a result of stock option exercises was approximately $1.7 billion, $1.5 billion and $2.0 billion for fiscal 2021, 2020 and 2019, respectively",2000000000.0
0.5013245940208435,marketable securities,"may 31, 2021 and 2020",$971 million,2021,"our non-marketable equity securities and related instruments totaled $971 million and $219 million as of may 31, 2021 and 2020, respectively, and are included either in other current assets or in other non-current assets in the accompanying consolidated balance sheets and are subject to periodic impairment reviews and adjustments for observable price changes from orderly transactions",971000000.0
0.3348462283611297,marketable securities,fiscal 2021,$299 million,2021,"non-operating income, net in fiscal 2021 included a $299 million unrealized investment gain for certain non-marketable securities due to an observable price change and a $193 million unrealized investment gain associated with certain marketable equity securities that we held for certain employee benefit plans and classified as trading, and for which an equal and offsetting amount was recorded to our operating expenses during the same period.",299000000.0
0.2632721960544586,marketable securities,fiscal 2021,$299 million,2021,"our non-operating income, net increased in fiscal 2021 compared to fiscal 2020 primarily due to higher other income, net that primarily resulted from a $299 million unrealized investment gain for certain non-marketable securities due to an observable price change and a $193 million unrealized investment gain associated with certain marketable equity securities that we held for certain employee benefit plans and classified as trading, and for which an equal and offsetting amount was recorded to our operating expenses during the same period",299000000.0
0.2494525015354156,marketable securities,march 2021,$15.0 billion,2021,"the increase in cash, cash equivalents and marketable securities at may 31, 2021 in comparison to may 31, 2020 was primarily due to cash inflows generated by our issuance of $15.0 billion of long-term senior notes in march 2021, cash inflows generated by our operations and cash inflows from stock option exercises during fiscal 2021",15000000000.0
0.1826615780591964,r&d value,"fiscal 2021, 2020",$6.5 billion,2020,"in fiscal 2021, 2020 and 2019, we invested $6.5 billion, $6.1 billion and $6.0 billion, respectively, in research and development to enhance our existing portfolio of offerings and products and to develop new technologies and services",6500000000.0
